00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Commercial insurers covered just 7.8% of the country’s innovative drug and device market last year, as pricing, data and access barriers continue to constrain growth. Photo: IC photo
Despite efforts to ease pressure on state-run healthcare, commercial insurers covered just 7.8% of the country’s innovative drug and device market last year, as pricing, data and access barriers continue to constrain growth
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Commercial insurers covered just 7.8% of the country’s innovative drug and device market last year, as pricing, data and access barriers continue to constrain growth. Photo: IC photo

China's drug sales skyrocket in 2025, white paper shows

China’s biotech boom drives surge in home-grown innovative drug approvals

Brand-name drug prices climb after launch in US, fall abroad amid MFN push: report

Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap

As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?

SR One’s Simeon George on how China is rewriting biotech’s venture playbook

Nuove tensioni tra Usa e Cina: adesso è scoppiata "la guerra dei farmaci"

The sales volume of China's innovative drugs and medical devices surged in 2025, while commercial insurance has become an…

The country’s drug evaluation agency registered a jump in new drug and clinical trial applications, signaling a robust pivot…

‘If we’re not careful, every drug could be made in China,’ warned former head of US Food and Drug Administration in May.

Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.

The FDA's new path, the status of animal testing, and other biotech news from The Readout

The city’s shift away from proportional reimbursement requires patients to pay the difference for expensive original drugs,…